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Open access under CC BY‘‘Weight of Evidence’’ (WoE) approaches are often used to critically examine, prioritize, and integrate
results from different types of studies to reach general conclusions. For assessing hormonally active
agents, WoE evaluations are necessary to assess screening assays that identify potential interactions with
components of the endocrine system, long-term reproductive and developmental toxicity tests that
deﬁne adverse effects, mode of action studies aimed at identifying toxicological pathways underlying
adverse effects, and toxicity, exposure and pharmacokinetic data to characterize potential risks. We
describe a hypothesis-driven WoE approach for hormonally active agents and illustrate the approach
by constructing hypotheses for testing the premise that a substance interacts as an agonist or antagonist
with components of estrogen, androgen, or thyroid pathways or with components of the aromatase or
steroidogenic enzyme systems for evaluating data within the US EPA’s Endocrine Disruptor Screening
Program. Published recommendations are used to evaluate data validity for testing each hypothesis
and quantitative weightings are proposed to reﬂect two data parameters. Relevance weightings should
be derived for each endpoint to reﬂect the degree to which it probes each speciﬁc hypothesis. Response
weightings should be derived based on assay results from the test substance compared to the range of
responses produced in the assay by the appropriate prototype hormone and positive and negative con-
trols. Overall WoE scores should be derived based on response and relevance weightings and a WoE nar-
rative developed to clearly describe the ﬁnal determinations.
 2011 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
On November 4, 2010, the US EPA released its draft ‘‘Weight-of-
Evidence Guidance Document: Evaluating Results of EDSP Tier 1
Screening to Identify Candidate Chemicals for Tier 2 Testing’’ (US
EPA, 2010). The Agency stated in its guidance that it would use
WoE to determine whether a chemical has the potential to interact
with the estrogen, androgen, or thyroid hormone components of& Toxicology, Inc., 2250 NW
335 8242.
.J. Borgert), emihaich@nc.rr.-
o), karin.s.bentley-1@usa.du-
asf.com (C.M. Holmes),
ker@americanchemistry.com
-NC-ND license.the endocrine system. EPA stated that the intent of the document
was ‘‘. . .to provide a transparent scientiﬁc approach for broadly
evaluating Tier 1 screening data to determine if additional Tier 2
testing is necessary.’’ EPA asserted its draft Guidance document
provided a clear statement of how EPA intended to evaluate Tier
1 data so that the Agency’s methodology would be transparent to
all stakeholders.
The draft EPA WoE Guidance offers only some general consider-
ations and principles related to making WoE determinations with-
in the Endocrine Disruptor Screening and Testing Program (EDSP),
and this may be viewed by some as providing a desired degree of
ﬂexibility for accommodating expert judgments within the
efﬂuvium of regulatory analyses and decision-making under
uncertainty. However, the draft Guidance falls well short in
describing how a WoE approach for the EDSP will be structured,
how data will be evaluated for use in WoE, how the endpoints
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will be weighted, or even how a weighing mechanism should be
developed. A direct, transparent and objective methodology is still
needed that will provide for consistency and credibility of WoE
determinations made on the basis of EDSP data. A transparent
and objective WoE methodology is especially necessary for the
EDSP given the EPA’s (and industry’s) lack of experience conduct-
ing the ESB, the broad scope of the program, the signiﬁcant impact
inaccurate assessment could have on society and the regulated
industry, and the excessive numbers of laboratory animals and
costs required for Tier 2 testing.
The EDSP consists of two distinct tiers. Tier 1 is intended to
determine whether a substance may interact with the endocrine
system. Tier 1 consists only of screening assays, which are not
sufﬁcient alone to determine whether substances may have ad-
verse health effects or to determine mode of action. Negative
Tier 1 results would be adequate to determine that a substance
is unlikely to have an effect on the estrogen, androgen or thyroid
hormone systems or aromatase and steroidogenic enzymes. Posi-
tive Tier 1 results would indicate that the substance should be
prioritized for Tier 2 testing. Tier 2, which consists of more api-
cal assays, is intended to determine whether a substance may
cause adverse effects, including those potentially mediated by
the endocrine system, and evaluate the dose response associated
with such effects. Tier 2 testing is more deﬁnitive than Tier 1
screening and negative Tier 2 results should supersede positive
Tier 1 results (US EPA, 1998).
It is clear that screening assays provide qualitatively different
information than deﬁnitive Tier 2 tests, and the results from these
dissimilar assays should be used in a manner that is consistent
with the scientiﬁc basis and purpose of each. The framework for
conducting WoE evaluations for hormonally active agents pro-
posed here is meant to operate within EPA’s two-tiered EDSP and
is intended to assist analysts in making the appropriate distinc-
tions. Given the structure of EPA’s EDSP, ﬁve separate WoE evalu-
ations will be needed to assess EDSP data and to make the
following determinations:
[a] determining from the Tier 1 ESB and other scientiﬁcally
relevant information (OSRI) whether a substance exhibits
the potential for interaction with androgen, estrogen, or
thyroid pathways or aromatase and steroidogenic enzymes
in vivo;
[b] determining from the Tier 1 ESB, OSRI and other information
whether the substance should be further evaluated for endo-
crine activity in Tier 2 toxicity tests;
[c] determining from the results of Tier 2 toxicity tests whether
a substance exhibits adverse effects potentially mediated by
androgen, estrogen, or thyroid pathways;
[d] determining from Tier 1 ESB, OSRI, Tier 2 toxicity tests, and
as necessary, additional mode-of-action experiments,
whether the adverse effects observed in Tier 2 toxicity tests
are a consequence of endocrine activity, and;
[e] determining whether endocrine-mediated adverse effects on
humans or wildlife are possible at environmentally relevant
exposure levels.
The framework for conducting WoE evaluations described here
is applicable to all ﬁve of these separate determinations. This pub-
lication describes the elements of the framework, including its
relationship to other published WoE approaches for endocrine ac-
tive substances, the overarching scientiﬁc principles that govern
data evaluation within the framework, and the two primary
weighting types used to evaluate data for each WoE determination.
This publication does not, however, describe the operational and
technical details necessary to carry out the ﬁve individual WoEdeterminations. Subsequent publications will provide those. In-
stead, this paper focuses on the principles and processes for
weighting data and illustrates how this is to be done for Tier 1
ESB data, i.e., for WoE determination [a] above.
Before delving further into the background literature and scien-
tiﬁc principles governing the proposed framework, it is imperative
to deﬁne terminology clearly so that the WoE framework can be
considered in its proper context. Weed (2005) has noted that the
term ‘‘weight of evidence’’ is used frequently in the scientiﬁc liter-
ature without being deﬁned. According to Weed, the term is used
in three categorically distinct ways: (1) metaphorical, (2) method-
ological, and (3) theoretical. As used in the framework proposed
here, the term ‘‘weight of evidence’’ is both theoretical in that it la-
bels the overall process, as well as methodological in that it de-
scribes speciﬁc methods and qualitative principles governing the
use of the proposed process. In subsequent publications, various
quantitative procedures will be described that might be used to
weight data from the various types of studies relevant for evaluat-
ing potential endocrine activity and endocrine-mediated toxicity.
Importantly, the framework proposed here incorporates step-by-
step documentation and transparency of the decision process,
which have been identiﬁed as elements that enhance scientiﬁc
credibility (Borgert, 2007a,b; Schreider et al., 2010).
The proposed WoE approach can be summarized according to
the following seven steps, the justiﬁcation and background
(Section 2), scientiﬁc principles (Section 3), operational details
(Sections 4 and 5), and implications (Section 6) of which are
explained further in this paper and in the tabular summaries
available as Supplementary material:
1. deﬁne speciﬁc hypotheses to be evaluated;
2. systematically search, review and select data relevant to each
hypothesis;
3. evaluate the primary validity and reliability of each study
selected, and for WoE evaluations involving causality (e.g., [c]
and [d] above), determine whether the data are derived from
counterfactually designed studies;
4. develop quantitative or rank ordered relevance weightings
(WREL) for each type of assay or endpoint with respect to its sen-
sitivity and speciﬁcity for testing the hypothesis;
5. develop quantitative response weightings (WRES) based on
results for the test substance compared to positive and negative
controls in each assay or endpoint;
6. combine relevance (WREL) and response (WRES) weightings
according to a pre-deﬁned algorithm to produce an overall
WoE score;
7. develop an overall WoE determination as to whether each
hypothesis is supported or rejected, and how strongly, based
on the overall WoE scores.
2. Background and justiﬁcation
Several organizations have developed frameworks and dis-
cussed principles important for conducting WoE evaluations (Balls
et al., 2006; Bars et al., 2011; Boobis et al., 2006, 2008; Damstra
et al., 2002; ECETOC, 2009; Gray et al., 2001; Menzie et al., 1996)
and independent investigators have published WoE frameworks
and evaluations of endocrine active substances (e.g., Calabrese
et al., 1997; Goodman et al., 2006, 2009; Martin et al., 2007; Rhom-
berg, 1998, 2008; Rhomberg and Goodman, 2008). It is beyond our
scope to summarize each of these frameworks and publications,
but a general overview is provided in the overview of weight of
evidence frameworks in Supplementary material, which is helpful
for understanding overarching issues related to developing WoE
frameworks and is essential for understanding our proposed
framework in the context of this previous work.
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formulated for making WoE decisions within the US EPA’s Tier 1
EDSP, and do not provide ‘off-the-shelf’ readiness ﬁt for this spe-
ciﬁc purpose. In particular, those frameworks do not address the
question of deciding whether a substance should be subjected to
Tier 2 testing based on the results of Tier 1 ESB data and integrated
with existing OSRI. Now that the EDSP 890 Series Test Guidelines
(US EPA, 2009) have been issued, it is possible to develop a more
complete and speciﬁc WoE framework to address the particular
needs of the EDSP program. It was therefore determined that a
new, thoroughWoE approach should be developed, speciﬁcally tai-
lored for use in the context of the EDSP. This new approach should
incorporate and build upon strengths of the prior work done in this
area, taking care to avoid pitfalls and ﬁll critical deﬁciencies noted
by analysts who have surveyed WoE methodologies (Krimsky,
2005; Schreider et al., 2010; Weed, 2005). In contrast to previously
mentioned frameworks, this new approach should clearly deﬁne
its scientiﬁc foundation, should provide a mechanism for actually
‘weighing’ evidence, and should clearly describe the derivation of
that weighting mechanism.
The approach proposed here seeks to leverage the consider-
able strengths of published WoE frameworks and evaluations.
Chief among these is a focus on speciﬁc hypotheses to be evalu-
ated by the WoE methodology, as advocated by Rhomberg and
colleagues (Goodman et al., 2006, 2009; Rhomberg, 1998;
Rhomberg and Goodman, 2008). Unambiguous hypotheses
enhance the clarity with which assays and endpoints can be
assigned as relevant for speciﬁc evaluations. Furthermore, clear
hypotheses should allow a more focused weighting of the various
assays and endpoints on the basis of empirical data rather than
the application of expert judgment alone. The hypothesis-driven
basis of the proposed approach will ideally allow assignment of
a quantitative relevance weighting for each endpoint and each
assay in the Tier 1 ESB. At the least, it should allow a semi-
quantitative rank ordering of the assays and endpoints based
on empirical observations.3. Overarching scientiﬁc principles
In developing a WoE framework, a number of overarching sci-
entiﬁc principles must be considered. First, relevant, testable
hypotheses should be developed. Data relevant to each hypothe-
sis should be gathered from mandated guideline studies or from
the literature according to clearly stated methods and criteria
for search and selection, similar to rules used to develop system-
atic reviews (Farquhar and Vail, 2006; Gronseth, 2004; McQueen,
2001; Oosterhuis et al., 2004; Ricci et al., 2006; Smyth, 2000; Zaza
et al., 2000). Data should then be evaluated in terms of minimal
epistemic status, reliability, and probative nature of the study de-
sign for evidence of causation (Borgert and Gori, in preparation;
Gori, 1999, 2001, 2002, 2009a, 2009b, 2010; Klimisch et al.,
1997; Schneider et al., 2009; Subcommittee on Energy and
Environment, 2010; Subcommittee on Health, 2010), which we
designate primary, secondary, and tertiary validity, respectively.
A detailed discussion of these fundamental scientiﬁc principles
and how they relate to the WoE framework proposed here for
the ESDP is provided in Building the Weight of Evidence Frame-
work on Scientiﬁc Principles found in Supplementary material.
The Supplementary material is essential for understanding the
proposed WoE framework, and the approach cannot be evaluated
or applied without it. It is important to clarify that the purpose of
these principles is not to exclude data on the basis of low pri-
mary, secondary, or tertiary validity, but that this evaluation be
reﬂected in the overall relevance weighting WREL of the endpoint
or data.4. WoE determination [a]: potential activity in Tier 1 screening
battery
In order to illustrate the proposed approach, details of the
framework for WoE evaluation [a] are described. As discussed
above, the ﬁrst step in developing a WoE framework is to develop
relevant hypotheses. Using the US EPA’s Tier 1 ESB as a working
example, eight discrete hypotheses are proposed for conducting a
WoE evaluation for determination [a] – determining whether a
substance exhibits the potential to interact with androgen, estro-
gen, or thyroid pathways in vivo, as follows:
[a] The chemical exhibits the potential to:
[a]-1 interact as an agonist with components of estrogen
pathways.
[a]-2 interact as an antagonist with components of estrogen
pathways.
[a]-3 interact as an agonist with components of androgen
pathways.
[a]-4 interact as an antagonist with components of androgen
pathways.
[a]-5 interact as an agonist with components of thyroid
pathways.
[a]-6 interact as an antagonist with components of thyroid
pathways.
[a]-7 interact with components of aromatase enzyme system.
[a]-8 interact with components of steroidogenesis enzyme
system.
Evaluating each hypothesis requires a clear understanding of
the results for each assay based on prototypical active (positive
control) and inactive (negative control) chemicals in each of the
EDSP Tier 1 ESB assays. This understanding should include an
evaluation of the validity of each endpoint measured in the assay
as described in Section 3 above. Ideally, the analyst’s understand-
ing would also include the positive and negative predictive value
of each endpoint in each assay – i.e., its sensitivity and speciﬁcity
– for predicting adverse endocrine-mediated effects in Tier 2 tests.
Both aspects should be accounted for by a quantitative weighting
of each endpoint for use in the WoE evaluation. This will provide
a ‘‘relevance weighting’’ for each endpoint and assay, for each
hypothesis, denoted by WREL. An alternative to this quantitative
assignment of WREL values would be to assign a rank ordering of
relevance for each endpoint for each hypothesis.
It is important to understand thatWREL values (or rank orderings)
need to be assigned for each endpoint that is relevant for each of the
eight hypotheses [a]-1 through [a]-8. These WREL values would be
expected to differ for each hypothesis, but not all endpoints have
relevance for each hypothesis. In other words, some endpoints will
have a WREL value of zero for some hypotheses, irrespective of the
strength and validity of that endpoint for its intended purpose. For
example, a zero WREL value might be assigned to the uterotrophic
response for evaluating hypothesis [a]-6, that a chemical has
potential to interact as an antagonist with components of thyroid
pathways, even though it may have a very high WREL value for
evaluating hypothesis [a]-1 (potential to interact as an agonist with
components of the estrogen pathway). It is also important to under-
stand that differentWREL values (or rank orderings) may need to be
assigned for different WoE determinations [a] through [e]. In other
words, the WREL value for the uterotrophic response may be quite
different for evaluating hypothesis [a]-1 (estrogen agonist pathway)
than for hypotheses related to WoE determination [c], whether a
substance exhibits adverse effects potentially mediated by andro-
gen, estrogen, or thyroid pathways.
Because the validation programs for endocrine screening assays
included in the US EPA’s Tier 1 ESB did not include a formal
Table 1
Male Pubertal Assay Example – Hypothesis [a]-6; Test agent acts as an antagonist with components of thyroid pathways in vivo.
⁄ To include consideration of dose response, statistical signiﬁcance and biological signiﬁcance.
⁄⁄ WREL values for the various endpoints would be expected to differ depending upon the hypothesis under evaluation. Some endpoints might have no relevance for a
particular hypothesis.
188 C.J. Borgert et al. / Regulatory Toxicology and Pharmacology 61 (2011) 185–191assessment of positive and negative predictive value, that informa-
tion is unlikely to be available until the results of screening assays
for the ﬁrst EDSP pesticide chemicals placed under test order are
completed, compiled, and evaluated. In lieu of those data and eval-
uations, an interim approach for assigningWREL values would be to
assign the weighting based on an evaluation of the relative validity
of the endpoints and any data available from relevant and reliable
published literature and from regulatory GLP studies. This process
and the data used should be fully described in the WoE evaluation,
in accordance with principles described here for evaluating pri-
mary, secondary and tertiary validity. Individual analysts could as-
sign WREL values on a case-by-case basis; however, greater
consistency would be achieved by holding expert consensus work-
shops to establishWREL values. The consensus workshops could de-
cide whether WREL values or rank orderings are more useful and
practical, and similar panels could update these as more complete
information emerges from the ﬁrst round of EDSP screening.
The actual results of each assay for each substance evaluated in
the ESB can be arrayed alongside the ‘‘expected results’’ of proto-
typical active and inactive agents. This comparison would seem
to be most transparent if a quantitative rating is also given to the
response produced by the test article. The weighting should reﬂect
the fact that the endpoints measured are typically continuous vari-
ables and not ordered responses. Thus, we propose that the re-
sponse of the test article be weighted according to a scale that
assigns the prototypical active agent, or positive control, the high-
est positive weighting for each endpoint and the negative control
the lowest. This addresses the ECETOC recommendation to con-
sider potency inWoE determinations regarding all aspects of endo-
crine activity, and addresses Krimsky’s criticism that WoE
methodologies often involve transforming continuous data to
dichotomous or triadic variables via black box judgments. This pro-
posed ‘‘response weighting’’ is denoted by WRES, for the test article
at the speciﬁc endpoint or assay.
The WoE evaluation for Tier 1 ESB would proceed for each
hypothesis by completing a tabular summary for each hypothesis
[a]-1 through [a]-8. The ﬁrst tabular summary involves input ofdata from the endpoints measured in each Tier 1 ESB, as well as
data obtained from published literature or other sources (e.g.,
OSRI). To illustrate the concept, Table 1 shows a portion of this ﬁrst
tabular summary listing endpoints from the male pubertal assay to
be evaluated for Hypothesis [a]-6, interaction as a thyroid hormone
antagonist. This process would be conducted for each hypothesis
[a]-1 through [a]-8, so that a complete tabular summary would
be repeated for each hypothesis (see Supplementary material,
Table A). The second tabular summary (see Supplementary mate-
rial, Table B) compiles the results of the ﬁrst tabular summary by
deriving an overall weighting for each assay for each hypothesis;
Supplementary material Table B provides an example using
Hypothesis [a]-6. Table B would also be repeated for each hypoth-
esis, resulting in 8 iterations, one for each hypothesis [a]-1 through
[a]-8. The third tabular summary (Table 2) compiles the results of
all eight iterations of Table B. A WoE narrative should accompany
Table 2 to describe the overall determination as to whether the ac-
tual data from the test article sustains or refutes each hypothesis
[a]-1 through [a]-8, supported by an explanation and rationale that
includes comparison of WoE scores for known positive and nega-
tive substances. All mitigating circumstances or conditions should
be described, such as equivocal results in some assays. It is recom-
mended that the analyst or expert panel derive a standard lexicon
for stating the results of the determinations, similar to the recom-
mendations of IPCS (Boobis et al., 2006, 2008). For example, a stan-
dardized determination might be:
‘‘Evidence is considered sufﬁcient/insufﬁcient/equivocal to indicate
the test article, under conditions of the experiments, has the poten-
tial to interact with one or more components of the Estrogen path-
way system in an agonistic manner.’’ Rationale: . . .’’5. WoE determinations [b] through [e]
WoE determinations [b] through [e] are not developed in detail
in this report, but will comprise subsequent publications. In gen-
eral, the basic components of the proposed WoE framework should
Table 2
WoE Determination [a]: determining from the Tier 1 ESB and OSRI whether a substance exhibits the potential for interaction with androgen, estrogen, or thyroid pathways in vivo
A WoE narrative should accompany Table 2 to describe the overall determination as to whether the actual data from the test article supports or refutes each hypothesis [a]-1
through [a]-8. Each determination should be supported by an explanation and rationale that includes comparison of WoE scores for known positive and negative substances.
All mitigating circumstances or conditions should be described, such as equivocal results in some assays.
C.J. Borgert et al. / Regulatory Toxicology and Pharmacology 61 (2011) 185–191 189be applied to each of the ﬁve WoE determinations. For WoE
determination [b] – deciding whether Tier 2 testing is warranted
– a consideration should be made of OSRI and other toxicity infor-
mation to determine whether the potency for a potential endocrine
activity could manifest actual toxicity that would be relevant for
human health or for human or ecological risk assessment. For
WoE determinations [c] through [e], the proposed method should
be used for weighting relevance and response as a ﬁrst step before
proceeding to the ﬂow charts presented in the ECETOC guidance
(Balls et al., 2006; ECETOC, 2009). For each step stated or implied
by the ECETOC framework, explicit hypotheses should be devel-
oped, and the principles and criteria for reliability, validity, and
transparency outlined herein should be applied in evaluating the
data used in these determinations.
The order of WoE determinations proposed here is not rigid.
For protecting public health, it may be more important to deter-
mine whether the potential endocrine-mediated effects identi-
ﬁed in Tier 2 testing (WoE determination [c]) are possible at
levels of exposure occurring in humans (WoE determination
[e]) than to determine unequivocally that the adverse effects
are indeed produced by an endocrine mechanism (WoE determi-
nation [d]). The salience of this point owes, in part, to the difﬁ-
culty of fully establishing the mechanism of action for any
particular effect, especially for chemicals that produce a variety
of biological effects within the same dose range. For systemic
toxicants, it may be challenging to differentiate toxic effects at
target organs mediated by non-endocrine modes of action from
weak endocrine activity. Furthermore, the types of adverse effect
endpoints evaluated in Tier 2 are not speciﬁc to a particular
endocrine pathway and may also occur as a result of toxicity
unrelated to any endocrine activity. Hence, these may or may
not be causally associated with Tier 1 results.
6. Discussion
Scientiﬁc conclusions in the health and environmental ﬁelds are
rarely made on the basis of a single evidentiary modality, thusWoE
approaches are needed to draw evidence from a variety of different
modalities with the expectation of convergence upon a coherent
and consistent conclusion (Krimsky, 2005). Krimsky explains that
because convergence is often elusive and data are often contradic-
tory, WoE approaches designed to ‘‘test’’ or evaluate convergencetypically rely on expert judgments to declare which lines of
evidence are stronger and thus, which evidence should be
weighted most heavily. Although Krimsky’s criticism of such judg-
ments seems sound, the solutions proposed here are not to im-
prove expert judgments but to enhance the role of hypothesis
generation and testing in WoE evaluations.
Although it is impossible to completely remove expert judg-
ment from the scientiﬁc process, the scientiﬁc method itself calls
for removal of the scientist or analyst as far as possible from the
generation and interpretation of data. To this end, the WoE
methodology proposed here is intended to render as much of
the decision-making process as possible data-dependent. In order
to do this, the framework relocates judgmental aspects that are
typically made in analysis and interpretation to the process of
methodological formulation, and this methodology has in turn
been tied as closely as possible to inference based on data from
speciﬁc assays and endpoints. This should not be interpreted as
suggesting box checking over scientiﬁc judgment, but rather as
elevating well-formulated inference based on objective data
above so-called ‘‘expert judgments.’’ This promotes standardiza-
tion of data review and evaluation approaches, encourages use
of standard procedures for evidence identiﬁcation, focuses
analysis based on an understanding of mode of action, and
standardizes the approach for conducting the weight-of-evidence
evaluation. These objectives and design features are indistin-
guishable from the recent recommendations of the National
Research Council for improving EPA risk assessments (NRC,
2011).
At the same time, it must be acknowledged that experimental
selection and design involves scientiﬁc judgment, and that even
this process entails a subjective component. This is addressed with
a formal statement about, and criteria by which to judge, the valid-
ity of the data brought to bear in the WoE evaluation. Although
these procedures cannot completely remove expert judgment from
theWoE process, they afford a means of dealing transparently with
these issues as objectively as possible.
Some may see this WoE framework as one pole of the spectrum
of approaches a regulatory agency may use to make decisions, with
the opposite pole being extreme interpretation of the precaution-
ary principle. It is acknowledged that the proposed approach
may appear tedious, resource intensive, and that equivalent
requisite data are unlikely to be available for many of the WoE
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imperfect. It would seem, however, that the numerous imperfec-
tions that may arise from disparate datasets are at least identiﬁable
and therefore transparent, and pale in contrast to the numerous
but hidden imperfections that are certain to arise by WoE pro-
cesses wholly dependent on expert judgments.
Clearly, the level of detail, rigor, and quantiﬁcation within a
WoE evaluation process should be commensurate with the nature
or impact of the decision being reached. In addition to risk, bene-
ﬁts, cost considerations, and societal concerns all play important
roles in regulatory policies and decision-making. Regulatory deci-
sions must consider economic costs of testing and regulation, the
need for health protection and the potential costs of adverse health
effects. But, as the Bipartisan Policy Center (BPC, 2009) panel con-
cluded in their report entitled Improving the Use of Science in Reg-
ulatory Policy, ‘‘science can inform some policy choices, but it can’t
determine them,’’ and that regulatory processes must be developed
that ‘‘explicitly differentiate, to the extent possible, between questions
that involve scientiﬁc judgments and questions that involve judgments
about economics, ethics and other matters of policy.’’ Moreover, the
considerable resources necessary to conduct WoE evaluations by
the method proposed here would seem well warranted for a pro-
gram that could represent a burden to the US economy in excess
of one hundred million dollars (Borgert et al., 2011). This proposed
WoE method aligns with these BPC recommendations, as evi-
denced by its focus on increasing the scientiﬁc rigor and transpar-
ency of endocrine WoE analyses.
Despite making speciﬁc methodological recommendations
about hypothesis formulation, evaluation of data validity, and
development of quantitative weightings, no speciﬁc recommenda-
tions are made here regarding several likely eventualities of endo-
crine screening and testing. These will need to be addressed either
by individual analysts, consensus workshops, or future publica-
tions. Although it is beyond the scope of this overall framework
to address each possible eventuality, several should be mentioned
for completeness.
For example, since the repetition of certain assays or similar
types of assays is likely, both conﬁrmatory and contradictory re-
sults are possible from endocrine screening and toxicology stud-
ies. While it would seem reasonable for conﬁrmatory results to
increase and contradictory results to decrease overall WoE
weightings, it is not immediately apparent how a simple quanti-
tative algorithm could address this consideration without sub-
jecting WoE determinations to the potential inﬂuence of the
replication number for certain assays. Similarly, the possibility
exists for in vitro and in vivo results to differ and for epidemio-
logical data to contradict data from experimental laboratory sys-
tems. While there would seem to be widespread agreement that,
in general, in vivo assays should be given more credence than
in vitro assays (US EPA, 2010), this generalization may not be
appropriate in all instances and professional judgment will be
required to properly weight evidence from different biological
levels of organization. Furthermore, ‘strength of evidence’ may
be an important concept for considering some of these issues.
The ECETOC framework for combining animal and human data
elevates data based on the quality of the study (Bars et al.,
2011), which is appropriate in many contexts, but the relevance
of the test system must also be considered. Regardless of
whether or not analysts impose a hierarchy of data types used
to resolve potential contradictions, it is important that the ratio-
nale for doing so (or not) be provided and if imposed, the meth-
odology described in detail and applied consistently. In addition,
no recommendation is given here as to whether a threshold of
evidence is necessary for any particular WoE decision. This
may be desirable and necessary, but the details for establishing
such thresholds should be developed after WREL values areestablished for the determination, hence, it would be premature
to do in this general framework.
Finally, new methodologies should ultimately be tested to con-
ﬁrm accuracy and utility. However, since ‘‘weight of evidence’’
methodologies are developed speciﬁcally to ﬁll a gap created by
the lack of a deﬁnitive test, the only means of ‘testing’ them is
against other judgmental processes. One way of testing the ap-
proach proposed here would be to use it to evaluate, in a blinded
manner, data generated for chemicals with well-known endocrine
properties that produce speciﬁc adverse effects, as well as data for
chemicals that clearly lack such activity and toxicity. Use of the
proposed methodology should conﬁrm the known activities; if
deviations are found, these could be used to reﬁne the process it-
self or the individual WREL scores.
In conclusion, the proposed approach builds upon recent
advancements in the practice of WoE by incorporating the greatest
strengths of recently published frameworks and methodologies. As
such, it represents an advancement of previous work because it
provides a clear statement of the foundation upon which interpre-
tations are made and proposes speciﬁc criteria for evaluating the
status of the data used in the WoE evaluations. These improve-
ments are necessary to satisfy many legitimate criticisms delin-
eated by Krimsky (2005) and Weed (2005) and to ensure that
WoE evaluations conducted under the US EPA’s EDSP are objective,
transparent, consistent, and scientiﬁcally reliable. Toward that end,
the convening of consensus workshops should occur as soon as
possible to begin the critical work of developing objective and
transparent relevance weightings (WREL) for all of the Tier 1 ESB
endpoints that will be used in making WoE determinations under
the EDSP. Future publications are in development that will propose
a starting point for these important deliberations regarding the
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